It is most likely that the apoptosis of pancreatic cancer is more frequently induced in the patients with a high p-HSP27 ratio after gemcitabine therapy than in those with a low p-HSP27 ratio, and that this might be the reason for the difference in their respective survival periods. The gene discussed is HSPB1; the disease is familial pancreatic carcinoma.